Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
27 nov. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive...
The antiviral drugs market is anticipated to grow at a CAGR of 6.3% during the period 2022-2035, claims Roots Analysis
01 nov. 2022 15h00 HE
|
Roots Analysis
London, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Antiviral Drugs Market, 2022 – 2035” report to its list of offerings. The recent COVID-19 pandemic has...
Virology Market Valuation to Outstrip $5.27Bn by 2028 Growth Projection at 3.6% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
21 sept. 2021 08h51 HE
|
The Insight Partners
New York, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Virology Market: Key InsightsAccording to our latest study on “Virology Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type,...
Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
02 mars 2021 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering
26 août 2020 17h35 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event
04 déc. 2019 08h00 HE
|
Cocrystal Pharma, Inc.
– Presentation on Tuesday, December 10th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage...
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
09 août 2018 08h00 HE
|
Cocrystal Pharma, Inc.
– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for...
COCRYSTAL PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING
01 mai 2018 08h30 HE
|
Cocrystal Pharma, Inc.
TUCKER, GA and BOTHELL, WA, May 01, 2018 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP), (“Cocrystal” or the “Company”) a clinical stage biotechnology company focused on developing...